Here is a question that comes up at every serious ibogaine conference and almost never gets a satisfying answer: do Western clinics, researchers, and advocates owe something to the Bwiti, the central African religious tradition that has used iboga ceremonially for generations?
The instinctive answer, for most people in the ibogaine space, is yes. Of course they do. Western medicine extracted knowledge from an indigenous tradition, built a therapeutic industry around it, and the communities that stewarded the plant have seen none of the benefit. The moral logic seems obvious.
But spend some time with the history, and the obvious answer gets complicated fast.
The Case for Reciprocity
Start with what’s not in dispute. The Bwiti, practiced primarily by the Fang and Mitsogho peoples of Gabon, Cameroon, and Equatorial Guinea, have been using iboga as a sacrament for initiations, healings, and ancestor communication for a very long time. The ceremonial framework they developed: the specific dose ranges that produce visionary states without killing initiates, the multi-day container, the experienced guides, the role of community. All of it represents centuries of empirical trial and error. People died learning what works. The survivors passed down what they learned.
When Western researchers began studying ibogaine in the 20th century, they were working with a molecule that a living tradition had already mapped. Howard Lotsof, who first recognized ibogaine’s addiction-interruption effect in 1962, eventually traveled to Gabon to meet Bwiti elders. The French had isolated the alkaloid in 1901. Neither encounter came with a check.
A useful parallel: in the 1600s, Spanish colonizers in the Andes learned from indigenous peoples that cinchona bark treated fever. European scientists isolated quinine from that bark, and the compound became the backbone of malaria treatment that saved millions of lives globally. The Andean communities whose traditional knowledge pointed the way received nothing. That is now recognized as a clear historical wrong, a textbook case of biopiracy. The ibogaine story has the same basic shape.
ICEERS, the International Center for Ethnobotanical Education, Research, and Service, put it plainly in a 2020 MAPS Bulletin paper: “Extracting ibogaine from iboga and the traditional wisdom that has held it for generations results in a significant loss, as does the extraction of ibogaine from iboga without regard for reciprocity with the peoples and ecosystems at the source.” That is the reciprocity argument in its clearest form.
There is a third dimension to this that gets less attention than it deserves. The Bwiti may have, without framing it in clinical terms, developed practices that mitigated ibogaine’s most dangerous side effect.
In some Bwiti traditions, iboga is administered alongside plantain banana. In the Maminengobe ceremony, root bark is combined with plantain, honey, and clay. The stated Bwiti purpose is to intensify the experience. But plantain is rich in potassium, and the clinical literature on ibogaine fatalities is unambiguous: low potassium (hypokalemia) appears in every documented death where electrolytes were tested, sometimes as severe as 2 mM against a normal floor of 3.5 mM. Ibogaine’s primary cardiac mechanism involves the hERG potassium channel and the QT interval. Whether or not the Bwiti understood the pharmacology, the practice appears to have addressed the risk. That connection has not been studied. It probably should be.
The deeper parallel is in the music. Research by Uwe Maas and Susanne Strubelt documented that Bwiti ceremonial music drives theta-frequency brainwaves, the same frequencies associated with parasympathetic nervous system activation: what cardiologists call vagal tone. A 2006 paper on ibogaine fatalities and autonomic dysfunction states it plainly: “Gabonian healers prevent cardiac risks by inducing a trance-state with right-hemispheric and vagal dominance for several days.” Vagal dominance is the body’s parasympathetic brake on the heart’s electrical system. It is genuinely cardioprotective. The polyrhythmic music the Bwiti have played for generations may not just be amplifying the medicine. It may be protecting the heart while it does it.
None of this requires the Bwiti to have known the mechanism for the argument to hold. Western ibogaine clinics inherited a set of empirically-derived practices (dosing context, ceremonial container, music, communal presence) some of which appear to have safety properties that the clinical model stripped out and is now trying to reconstruct with magnesium IV drips and continuous EKG monitoring. That is worth naming.
There is also a practical concern that runs alongside the moral one. Global demand for iboga is rising. The root bark comes from a shrub native to a specific region of central Africa. Questions about sustainable harvesting and who controls the commercial supply of iboga are live and unresolved. The communities closest to the plant (geographically and historically) are not the ones profiting from the boom. That is a concrete present-tense problem, not just a historical grievance.
The Case That Complicates It
Here is where it gets harder.
The Bwiti tradition, as it exists today, is not an unbroken ancient lineage. Bwiti is syncretic. The most widespread form, Fang Bwiti, incorporated significant Christian elements during the colonial period, evolving through direct contact with French missionaries. The religion as practiced now is partly a colonial-era synthesis. This does not make it inauthentic, but it does complicate the idea that honoring Bwiti means honoring an untouched original.
More importantly, the Bwiti’s own origin myths acknowledge that they did not originate iboga use. Most Bwiti traditions credit the Babongo, the Pygmy forest peoples of central Africa, as iboga’s original keepers. One Fang creation account describes iboga as a gift passed from the creator through a Pygmy intermediary to the Bwiti. The religion itself preserves the receipt. If you follow the logic of reciprocity back to its source, you end up at the Babongo, not the Bwiti.
The same ICEERS paper that makes the strongest case for reciprocity quietly acknowledges this: “Iboga was used for centuries among Bantou communities of Gabon and was likely practiced among Pygmies in earlier times.” Even the most rigorous advocates for honoring the tradition are conceding, in the footnotes, that the tradition itself has a predecessor.
Which raises the question: what exactly is the origin point to which reciprocity is owed?
This is where the aspirin analogy is instructive, even if imperfect. Willow bark has been used to treat pain across ancient Egypt, Greece, Rome, and Native American cultures for thousands of years. Bayer isolated salicylic acid in the 19th century, acetylated it, and patented the result as Aspirin in 1899. The knowledge was ancient and widespread. Nobody argues for aspirin reciprocity today, and the main reason is that the source is too diffuse. There is no identifiable community to write the check to.
Iboga is not quite that diffuse (the Bwiti are a specific living community in an identifiable place), but the historical chain is messier than the clean biopiracy framing suggests.
There is also a chemical distinction worth naming. The ibogaine that a clinic in Mexico administers is ibogaine hydrochloride: a synthesized, purified alkaloid extracted from the plant and standardized to a precise dose. It is not iboga. The Bwiti initiation uses the whole root bark, in a completely different dose range, inside a completely different ceremonial container. The argument that ibogaine HCl in a clinical setting is “derived from Bwiti knowledge” is accurate in the sense that the molecule’s identity and approximate therapeutic potential were known to the tradition. But as anthropologist Julien Bonhomme observed in his 2023 MIT Press essay on iboga’s transnational history: “American treatments focus on ibogaine, the chemical molecule, and its psychoactive properties, whereas in Gabon the emphasis is placed on the iboga root itself, the plant in its natural state.” The pharmaceutical form, the dose protocol, and the clinical application represent enough independent development that the biopiracy frame starts to strain.